Gilead Sciences announced on Wednesday it would soon initiate two Phase 3 studies for Remdesivir for treatment of the coronavirus, which will include testing the drug on patients in countries most affected by the disease.”Gilead’s primary focus is on rapidly determining the safety and efficacy of remdesivir as a potential treatment for COVID-19,” the pharmaceutical company said in a statement.The study will be conducted on 1,000 patients, mostly in countries across Asia, who will receive the drug for ten days.